HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

L’Oréal “Women of Worth”

This article was originally published in The Rose Sheet

Executive Summary

Karen Stark - founder of the "HUGS Project," which sends "hugs" (handmade wearable items for warming or cooling, depending on the season) and care packages to U.S. troops serving overseas - is chosen by popular vote as L'Oreal's Women of Worth National Honoree. Voting for the award opened in early October (1"The Rose Sheet" Oct. 15, 2007, p. 8). Stark will receive $25,000 for the HUGS Project, on top of the $2,500 awarded to all 13 Women of Worth honorees for their respective non-profit and $2,500 donated in each woman's name to The Ovarian Cancer Research Fund, with which L'Oreal Paris has had a charitable partnership for 10 years, firm notes...

You may also be interested in...



L’Oreal Stresses Corporate Responsibility With Creation of L’Oréal Foundation

The L'Oréal Corporate Foundation is "an additional step in our determination to look beyond our economic success towards a broader notion of social responsibility," the company announces Oct. 9

Rising Costs, Price Pressure Usher In Uncertain Year Of The Rat In China

Once the world's factory, China has seen costs inch up while drug prices are being cut deeply by centralized procurement schemes. As uncertainties mount, companies need to focus on improving process and scale-up technology, suggested industry observers at a JPM panel discussion on innovation and market access challenges.

Biocon-Mylan's Plans For Broader US Fulphila Access, Glargine On Track

Biocon-Mylan press ahead with plans to broaden patient access in the US to biosimilar pegfilgrastim and are enthused with the initial uptake for their trastuzumab biosimilar ahead of more upcoming competition. A mid-2020 US launch for partnered insulin glargine is also on course.

UsernamePublicRestriction

Register

RS015059

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel